Furthermore, we compared the lethality of BMN673 with that of the other selected candidate inhibitors: a BET inhibitor (JQ1) (Supplementary Figure S2A), a JAK2 inhibitor (AZ960) (Supplementary Figure S2B), and three inhibitors with reported activity against H3K27M-mutant gliomas, namely, EPZ6438 (an EZH2 inhibitor) (Supplementary Figure S3A), sorafenib (a multikinase inhibitor) (Supplementary Figure S3B), and LBH589 (an HDAC inhibitor) (Supplementary Figure S3C). Here, DNER is linked to central nervous system cancer.